Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans

Antimicrob Agents Chemother. 2009 Jan;53(1):309-11. doi: 10.1128/AAC.01216-08. Epub 2008 Oct 27.

Abstract

We measured antifungal activity against 128 cryptococcal isolates (86 of C. neoformans and 42 of C. gattii) to determine if differences in serotype susceptibility exist. Contrary to previous results, we found no serotype susceptibility differences. Isavuconazole, posaconazole, and voriconazole demonstrated excellent potency against each isolate and serotype, including isolates with reduced fluconazole susceptibilities.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents / pharmacology*
  • Cryptococcus / classification
  • Cryptococcus / drug effects*
  • Cryptococcus neoformans / classification
  • Cryptococcus neoformans / drug effects*
  • Fluconazole / pharmacology
  • Microbial Sensitivity Tests
  • Nitriles / pharmacology
  • Pyridines / pharmacology
  • Pyrimidines / pharmacology
  • Serotyping
  • Triazoles / pharmacology
  • Voriconazole

Substances

  • Antifungal Agents
  • Nitriles
  • Pyridines
  • Pyrimidines
  • Triazoles
  • isavuconazole
  • posaconazole
  • Fluconazole
  • Voriconazole